Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways

Roberto Galuppo, Erin Maynard, Malay Shah, Michael F. Daily, Changguo Chen, Brett T. Spear, Roberto Gedaly

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background/Aim: The aim of this study is to find synergistic effect using FH535 and sorafenib by targeting the RAS/RAF/MAPK and WNT/β-catenin pathways. Materials and Methods: 3H-Thymidine incorporation assays were performed to address Huh7 and liver cancer stem cell (LCSC) inhibition using FH535 and sorafenib, alone and in combination. Calcusyn analysis was used to calculate the combination index (CI). A western blot assay was performed to check for potential targets. Results: FH535 and sorafenib caused inhibition of Huh7 and LCSC. Combination therapy was significantly better than monotherapy in inhibition of HuH7. Combination with sorafenib and FH535 was found to be synergistic in inhibition of LCSC with a CI of less than 1. The western blot assay demonstrated enhanced cleaved poly (ADP-ribose) polymerase (PARP) and inhibition of cyclin D1, B-cell lymphoma 2 (Bcl2), survivin and cellular myelocytomatosis oncogene (c-MYC). Conclusion: FH535 and sorafenib combination produced synergistic effect on inhibition of HCC and LCSC. Our study demonstrated that FH535 can induce apoptosis in these two different hepatocellular carcinoma (HCC) cell lines.

Original languageEnglish (US)
Pages (from-to)1709-1714
Number of pages6
JournalAnticancer Research
Volume34
Issue number4
StatePublished - Apr 1 2014
Externally publishedYes

Fingerprint

Catenins
Neoplastic Stem Cells
Liver Neoplasms
Hepatocellular Carcinoma
Cell Proliferation
Western Blotting
Cyclin B
Poly(ADP-ribose) Polymerases
Cyclin D1
B-Cell Lymphoma
Oncogenes
Thymidine
FH535
sorafenib
Apoptosis
Cell Line

Keywords

  • Epidermal growth factor
  • Hepatocellular carcinoma
  • Liver cancer stem cells
  • mTOR complex 1
  • mTOR complex 2
  • PI-103
  • PKI-587
  • Rapamycin
  • RAS/RAF/MAPK
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Galuppo, R., Maynard, E., Shah, M., Daily, M. F., Chen, C., Spear, B. T., & Gedaly, R. (2014). Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways. Anticancer Research, 34(4), 1709-1714.

Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways. / Galuppo, Roberto; Maynard, Erin; Shah, Malay; Daily, Michael F.; Chen, Changguo; Spear, Brett T.; Gedaly, Roberto.

In: Anticancer Research, Vol. 34, No. 4, 01.04.2014, p. 1709-1714.

Research output: Contribution to journalArticle

Galuppo, R, Maynard, E, Shah, M, Daily, MF, Chen, C, Spear, BT & Gedaly, R 2014, 'Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways', Anticancer Research, vol. 34, no. 4, pp. 1709-1714.
Galuppo, Roberto ; Maynard, Erin ; Shah, Malay ; Daily, Michael F. ; Chen, Changguo ; Spear, Brett T. ; Gedaly, Roberto. / Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways. In: Anticancer Research. 2014 ; Vol. 34, No. 4. pp. 1709-1714.
@article{26bab04e33c54e928b1fdc91ed61c034,
title = "Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways",
abstract = "Background/Aim: The aim of this study is to find synergistic effect using FH535 and sorafenib by targeting the RAS/RAF/MAPK and WNT/β-catenin pathways. Materials and Methods: 3H-Thymidine incorporation assays were performed to address Huh7 and liver cancer stem cell (LCSC) inhibition using FH535 and sorafenib, alone and in combination. Calcusyn analysis was used to calculate the combination index (CI). A western blot assay was performed to check for potential targets. Results: FH535 and sorafenib caused inhibition of Huh7 and LCSC. Combination therapy was significantly better than monotherapy in inhibition of HuH7. Combination with sorafenib and FH535 was found to be synergistic in inhibition of LCSC with a CI of less than 1. The western blot assay demonstrated enhanced cleaved poly (ADP-ribose) polymerase (PARP) and inhibition of cyclin D1, B-cell lymphoma 2 (Bcl2), survivin and cellular myelocytomatosis oncogene (c-MYC). Conclusion: FH535 and sorafenib combination produced synergistic effect on inhibition of HCC and LCSC. Our study demonstrated that FH535 can induce apoptosis in these two different hepatocellular carcinoma (HCC) cell lines.",
keywords = "Epidermal growth factor, Hepatocellular carcinoma, Liver cancer stem cells, mTOR complex 1, mTOR complex 2, PI-103, PKI-587, Rapamycin, RAS/RAF/MAPK, Sorafenib",
author = "Roberto Galuppo and Erin Maynard and Malay Shah and Daily, {Michael F.} and Changguo Chen and Spear, {Brett T.} and Roberto Gedaly",
year = "2014",
month = "4",
day = "1",
language = "English (US)",
volume = "34",
pages = "1709--1714",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-Catenin pathways

AU - Galuppo, Roberto

AU - Maynard, Erin

AU - Shah, Malay

AU - Daily, Michael F.

AU - Chen, Changguo

AU - Spear, Brett T.

AU - Gedaly, Roberto

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Background/Aim: The aim of this study is to find synergistic effect using FH535 and sorafenib by targeting the RAS/RAF/MAPK and WNT/β-catenin pathways. Materials and Methods: 3H-Thymidine incorporation assays were performed to address Huh7 and liver cancer stem cell (LCSC) inhibition using FH535 and sorafenib, alone and in combination. Calcusyn analysis was used to calculate the combination index (CI). A western blot assay was performed to check for potential targets. Results: FH535 and sorafenib caused inhibition of Huh7 and LCSC. Combination therapy was significantly better than monotherapy in inhibition of HuH7. Combination with sorafenib and FH535 was found to be synergistic in inhibition of LCSC with a CI of less than 1. The western blot assay demonstrated enhanced cleaved poly (ADP-ribose) polymerase (PARP) and inhibition of cyclin D1, B-cell lymphoma 2 (Bcl2), survivin and cellular myelocytomatosis oncogene (c-MYC). Conclusion: FH535 and sorafenib combination produced synergistic effect on inhibition of HCC and LCSC. Our study demonstrated that FH535 can induce apoptosis in these two different hepatocellular carcinoma (HCC) cell lines.

AB - Background/Aim: The aim of this study is to find synergistic effect using FH535 and sorafenib by targeting the RAS/RAF/MAPK and WNT/β-catenin pathways. Materials and Methods: 3H-Thymidine incorporation assays were performed to address Huh7 and liver cancer stem cell (LCSC) inhibition using FH535 and sorafenib, alone and in combination. Calcusyn analysis was used to calculate the combination index (CI). A western blot assay was performed to check for potential targets. Results: FH535 and sorafenib caused inhibition of Huh7 and LCSC. Combination therapy was significantly better than monotherapy in inhibition of HuH7. Combination with sorafenib and FH535 was found to be synergistic in inhibition of LCSC with a CI of less than 1. The western blot assay demonstrated enhanced cleaved poly (ADP-ribose) polymerase (PARP) and inhibition of cyclin D1, B-cell lymphoma 2 (Bcl2), survivin and cellular myelocytomatosis oncogene (c-MYC). Conclusion: FH535 and sorafenib combination produced synergistic effect on inhibition of HCC and LCSC. Our study demonstrated that FH535 can induce apoptosis in these two different hepatocellular carcinoma (HCC) cell lines.

KW - Epidermal growth factor

KW - Hepatocellular carcinoma

KW - Liver cancer stem cells

KW - mTOR complex 1

KW - mTOR complex 2

KW - PI-103

KW - PKI-587

KW - Rapamycin

KW - RAS/RAF/MAPK

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84900519241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900519241&partnerID=8YFLogxK

M3 - Article

C2 - 24692700

AN - SCOPUS:84900519241

VL - 34

SP - 1709

EP - 1714

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -